COVID‐19 pandemic and allergen immunotherapy—an EAACI survey

As in many fields of medical care, the coronavirus disease 2019 (COVID‐19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.

[1]  K. Schäkel,et al.  Healthcare provision for insect venom allergy patients during the COVID-19 pandemic , 2020, Allergo Journal International.

[2]  P. Turner,et al.  The Impact of COVID-19 Pandemic on Adult and Pediatric Allergy & Immunology Services in the UK National Health Service , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[3]  C. Azzari,et al.  Pediatric Allergy and Immunology Practice During the COVID-19 Pandemic in Italy: Perspectives, Challenges, and Opportunities , 2020, Frontiers in Pediatrics.

[4]  T. Luedde,et al.  [Perception of the COVID-19 Pandemic among Pneumology Professionals in Germany]. , 2020, Pneumologie.

[5]  T. Craig,et al.  Allergy/Immunology Trainee Experiences During the COVID-19 Pandemic: AAAAI Work Group Report of the Fellows-in-Training Committee , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[6]  E. Civelek,et al.  Change in Allergy Practice during the COVID-19 Pandemic , 2020, International Archives of Allergy and Immunology.

[7]  J. Shih,et al.  Patient satisfaction and utilization of telemedicine services in allergy: An institutional survey , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[8]  B. Masri,et al.  The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study , 2020, Clinical Rheumatology.

[9]  L. Carneiro-Leão,et al.  Real-life experience of an allergy and clinical immunology department in a Portuguese reference COVID-19 hospital , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[10]  K. Hoffmann‐Sommergruber,et al.  [Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)]. , 2020, Laryngo- rhino- otologie.

[11]  Abhishek Kumar,et al.  Impact of COVID-19 on U.S. and Canadian neurologists’ therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices , 2020, Journal of Neurology.

[12]  Todor A Popov,et al.  ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020) , 2020, Allergy.

[13]  K. Hoffmann‐Sommergruber,et al.  Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI) , 2020, Allergy.

[14]  C. Akdis,et al.  COVID‐19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS‐CoV‐2 infection and care of allergy patients , 2020, Allergy.

[15]  S. Rizzi,et al.  Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic , 2020, Italian Journal of Pediatrics.

[16]  Jae Hyun Lee,et al.  Management of Allergic Patients During the COVID-19 Pandemic in Asia , 2020, Allergy, asthma & immunology research.

[17]  J. Bousquet,et al.  A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2 , 2020, Allergy.

[18]  K. Hoffmann‐Sommergruber,et al.  COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper , 2020, Allergy.

[19]  S. Loosen,et al.  Impact of the COVID-19 Pandemic on Urologists in Germany , 2020, European Urology Focus.

[20]  J. Bousquet,et al.  Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement , 2020, Allergy.

[21]  Yuan Zhang,et al.  Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis , 2020, The Lancet.

[22]  C. Torp‐Pedersen,et al.  Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark , 2020, Circulation. Heart failure.

[23]  K. Hoffmann‐Sommergruber,et al.  Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA , 2020, Allergologie select.

[24]  P. Khoury,et al.  The Future of Telehealth in Allergy and Immunology Training , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[25]  S. Durham,et al.  EAACI Allergen Immunotherapy User's Guide , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[26]  S. Durham,et al.  Allergen Immunotherapy in Children User’s Guide , 2020 .

[27]  K. Hoffmann‐Sommergruber,et al.  Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement , 2020, Allergy.

[28]  G. Canonica,et al.  An academic allergy unit during COVID-19 pandemic in Italy , 2020, Journal of Allergy and Clinical Immunology.

[29]  Giselle Mosnaim,et al.  COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[30]  J. Portnoy,et al.  Telemedicine in the Era of COVID-19 , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[31]  Hui Du,et al.  Eleven faces of coronavirus disease 2019 , 2020, Allergy.

[32]  Beijing China. Prevention,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China , 2020 .

[33]  A. Muraro,et al.  Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis , 2020, Allergy.

[34]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[35]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.

[36]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[37]  T. Luedde,et al.  Perception of the 2020 SARS-CoV-2 pandemic among medical professionals in Germany: results from a nationwide online survey , 2020, Emerging microbes & infections.

[38]  J. Virchow,et al.  Perspectives in allergen immunotherapy: 2019 and beyond , 2019, Allergy.

[39]  K. Hoffmann‐Sommergruber,et al.  The role of mobile health technologies in allergy care: An EAACI position paper , 2019, Allergy.

[40]  K. Waibel,et al.  Outcomes From a Regional Synchronous Tele-Allergy Service. , 2019, The journal of allergy and clinical immunology. In practice.

[41]  N. Papadopoulos,et al.  Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry , 2018, Allergy.

[42]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[43]  A. Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Executive statement , 2018, Allergy.

[44]  Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy , 2018, Allergy.

[45]  A. Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Prevention of allergy , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[46]  Chitra Dinakar,et al.  American College of Allergy, Asthma & Immunology Position Paper on the Use of Telemedicine for Allergists. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[47]  P Demoly,et al.  Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper , 2017, Allergy.

[48]  A. Sheikh,et al.  Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis , 2017, Allergy.

[49]  C. Camargo,et al.  Allergen immunotherapy: No evidence of infectious risk. , 2016, The Journal of allergy and clinical immunology.

[50]  A. Fusi,et al.  Sublingual allergen immunotherapy in HIV‐positive patients , 2016, Allergy.

[51]  R. Van Ree,et al.  International consensus on allergy immunotherapy. , 2015, The Journal of allergy and clinical immunology.

[52]  P. Demoly,et al.  Clinical contraindications to allergen immunotherapy: an EAACI position paper , 2015, Allergy.

[53]  M. Calderón,et al.  Safety and Efficacy of Allergen Immunotherapy in Patients with HIV and Allergic Rhinitis: Facts and Fiction , 2015, Current Treatment Options in Allergy.

[54]  H. Sitter,et al.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases , 2014, Allergo Journal International.

[55]  Qun Li.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020 .

[56]  L. Ahmetaj,et al.  The Effect of Viral Infections and Allergic Inflammation in Asthmatic Patients on Immunotherapy , 2018 .

[57]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).